Compare · ICLR vs MEDP
ICLR vs MEDP
Side-by-side comparison of ICON plc (ICLR) and Medpace Holdings Inc. (MEDP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ICLR and MEDP operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- MEDP is the larger of the two at $17.14B, about 1.3x ICLR ($12.93B).
- ICLR has been more active in the news (19 items in the past 4 weeks vs 10 for MEDP).
- Both have 25 recent analyst ratings on file.
- Company
- ICON plc
- Medpace Holdings Inc.
- Price
- -
- -
- Market cap
- $12.93B
- $17.14B
- 1M return
- -
- +4.05%
- 1Y return
- -
- +30.65%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1998
- 2016
- News (4w)
- 19
- 10
- Recent ratings
- 25
- 25
ICON plc
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. The company's clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional solutions, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON has an agreement with Evergreen Therapeutics, Inc. to conduct Phase II clinical trial for COVID-19 drug candidate. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Latest ICLR
- SEC Form 6-K filed by ICON plc
- SEC Form 6-K filed by ICON plc
- Amendment: SEC Form SCHEDULE 13G/A filed by ICON plc
- Director O'Neill Julie converted options into 1,732 units of Ordinary Shares and sold $150,326 worth of Ordinary Shares (915 units at $164.29), increasing direct ownership by 30% to 3,515 units (SEC Form 4) to satisfy tax liability
- Director Whitaker Anne Clem converted options into 1,732 units of Ordinary Shares and sold $138,168 worth of Ordinary Shares (841 units at $164.29) (SEC Form 4) to satisfy tax liability
- Director Murray Ciaran sold $439,803 worth of Ordinary Shares (2,677 units at $164.29) and converted options into 2,677 units of Ordinary Shares (SEC Form 4) (for tax liability)
- Director Murphy Ronan Martin converted options into 1,732 units of Ordinary Shares and sold $138,168 worth of Ordinary Shares (841 units at $164.29), increasing direct ownership by 30% to 3,847 units (SEC Form 4) (tax withholding)
- Director Mccague Eugene Pacelli converted options into 1,732 units of Ordinary Shares and sold $138,168 worth of Ordinary Shares (841 units at $164.29), increasing direct ownership by 31% to 3,811 units (SEC Form 4) (tax liability)
- Director Grais Linda converted options into 1,732 units of Ordinary Shares and sold $138,169 worth of Ordinary Shares (841 units at $164.29), increasing direct ownership by 17% to 6,162 units (SEC Form 4) (for withholding tax)
- SEC Form 4 filed by Chief Accounting Officer Lyons Emer
Latest MEDP
- President & CEO Troendle August J. sold $9,969,094 worth of shares (15,978 units at $623.93), decreasing direct ownership by 3% to 545,217 units (SEC Form 4)
- CFO & Treasurer Brady Kevin M. exercised 3,400 shares at a strike of $138.87 and sold $2,125,816 worth of shares (3,400 units at $625.24) (SEC Form 4)
- President & CEO Troendle August J. sold $26,281,390 worth of shares (42,783 units at $614.30), decreasing direct ownership by 7% to 561,195 units (SEC Form 4)
- Director Carley Brian T sold $3,043,150 worth of shares (5,000 units at $608.63), decreasing direct ownership by 15% to 27,825 units (SEC Form 4)
- Director Davenport Fred B Jr exercised 7,583 shares at a strike of $116.08 and sold $4,414,590 worth of shares (7,283 units at $606.15), increasing direct ownership by 9% to 3,798 units (SEC Form 4)
- SEC Form 144 filed by Medpace Holdings Inc.
- President & CEO Troendle August J. sold $7,111,969 worth of shares (11,824 units at $601.49), decreasing direct ownership by 2% to 603,978 units (SEC Form 4)
- Director Mccarthy Cornelius P. Iii sold $690,122 worth of shares (1,140 units at $605.37), decreasing direct ownership by 8% to 12,275 units (SEC Form 4)
- President & CEO Troendle August J. sold $13,984,854 worth of shares (23,144 units at $604.25), decreasing direct ownership by 4% to 615,802 units (SEC Form 4)
- Director Mccarthy Cornelius P. Iii exercised 3,858 shares at a strike of $84.36 and sold $465,131 worth of shares (795 units at $585.07), increasing direct ownership by 30% to 13,415 units (SEC Form 4)